CHDI has access to a variety of relevant research tools, including in vitro and in vivo assays and animal models.
Intellect is the exclusive licensee of patents related to the use of Oxigon, which are owned jointly by New York University and the University of South Alabama Research Foundation. Patents have been granted in Europe, the US and several other countries.
Daniel Chain, CEO and chairman of intellect, said: “We are pleased that CHDI is evaluating whether Oxigon’s method of action might extend to Huntington’s disease. Oxigon is planned to enter Phase II clinical trials in Alzheimer’s patients in 2008. The data generated in the CHDI study could support proceeding with clinical trials in HD patients as well.”